JP Morgan Put 110 NVO 15.11.2024/ DE000JT7DBU2 /
2024-10-17 9:21:50 AM | Chg.0.000 | Bid10:00:26 AM | Ask10:00:26 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.230EUR | 0.00% | 0.240 Bid Size: 3,000 |
- Ask Size: - |
Novo Nordisk | 110.00 USD | 2024-11-15 | Put |
Newsfile Corp
08-28
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
08-28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
08-28
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
08-27
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
08-26
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
08-21
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
08-14
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
08-06
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
08-01
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
07-11
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
07-11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
07-11
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...